Navigation Links
Finkelstein Thompson LLP Announces GPC Biotech AG Investigation
Date:8/21/2007

WASHINGTON, Aug. 21 /PRNewswire/ -- The law firm of Finkelstein Thompson LLP announces that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all persons who purchased the common stock of GPC Biotech AG ("GPC Biotech" or the "Company") (Nasdaq: GPCB) between December 15, 2005 and July 24, 2007, inclusive (the "Class Period"). Finkelstein Thompson LLP is investigating similar claims at this time and welcomes investor inquiries.

The Complaint charges GPC Biotech and certain of the Company's executive officers with violations of federal securities laws. Specifically, the Complaint alleges that Defendants over the course of several years, GPC Biotech has been focused almost exclusively on efforts to develop and gain approval for Satraplatin, an oral drug therapy for advanced prostate cancer patients who have proved resistant to conventional treatments. The Complaint further alleges that, under increased pressure to gain FDA marketing approval, Defendants used improper testing methods to determine whether Satraplatin was safe and effective.

On July 24, 2007, the FDA disclosed that it had unanimously recommended against the approval of Satraplatin. The market responded sharply to this news on July 25, 2007 with the price of GPC Biotech stock falling $7.20 to close at $13.16, a drop of over 35%.

If you are a member of the class, you may, no later than September 24, 2007, request that the Court appoint you as lead plaintiff of the class. A lead plaintiff is a class member appointed by the Court to direct the litigation on behalf of the class. Although a class member need not be appointed as a lead plaintiff to receive a proportionate share of any proceeds of the litigation, lead plaintiffs make important decisions that could affect the prosecution of the class claims, including decisions concerning settlement. The securities laws create a rebuttable presumption that the plaintiff with the larges financial interest in the litigation is the most adequate to serve as lead plaintiff.

Finkelstein Thompson LLP has spent almost three decades delivering outstanding representation to institutional and individual clients in connection with securities and other finance-related litigation, and has been appointed as lead or co-lead counsel in dozens of shareholder class actions. Indeed, in the past decade, the firm has served in leadership roles in cases that have recovered over $1 billion for investors and consumers.

If you are a GPC Biotech shareholder and wish to discuss this matter or have information relevant to the investigation, please contact our Washington, DC office toll-free at (877) 337-1050, or by email at contact@finkelsteinthompson.com.


'/>"/>
SOURCE Finkelstein Thompson LLP
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Thompson in partnership to build ethanol plant
2. Tommy Thompsons Iowa strategy isnt far-fetched
3. Tommy Thompson says capital needed for electronic health records
4. Former Thompson lawyer comments on Doyle stem cell executive order
5. Reading Tommy Thompsons mind – life after public service
6. Thompsons HHS legacy will include efforts to combat disease in Africa
7. Tommy Thompson joins drug company as advisor
8. Tommy Thompson joins Picis board of directors
9. Tommy Thompson will speak at World Congress on IT next May
10. Reading Tommy Thompsons diary: Imagining unspoken thoughts about 2008
11. Tommy Thompson elected to board of Jersey medical firm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... Amendia, Inc., a leading designer, ... announced the completion of a significant transaction and partnership that positions Amendia for ... partners. Kohlberg & Company, L.L.C. (“Kohlberg”), a leading private equity firm specializing ...
(Date:4/29/2016)... ... ... Intelligent Implant Systems announced today that the two-level components for the Revolution™ Spinal ... These components expand the capabilities of the system and allow Revolution™ to be ... 2015, the company has seen significant sales growth in 1Q 2016, and the system ...
(Date:4/28/2016)... ... April 28, 2016 , ... Connecticut Innovations (CI), ... today announced the launch of VentureClash , a $5 million global investment ... “VentureClash looks to attract the best early-stage companies here in Connecticut, around the ...
(Date:4/27/2016)... ... , ... Cambridge Semantics, the leading provider of Smart Data analytic ... been named to The Silicon Review’s “20 Fastest Growing Big Data Companies of 2016.” ... the needs of end users facing some of the most complex data challenges in ...
Breaking Biology Technology:
(Date:3/11/2016)... http://www.apimages.com ) - --> http://www.apimages.com ) - ... Images ( http://www.apimages.com ) - Germany . ... new refugee identity cards. DERMALOG will be unveiling this device, and ... Hanover next week.   --> Germany ... the new refugee identity cards. DERMALOG will be unveiling this device, ...
(Date:3/9/2016)... 9, 2016 This BCC Research report provides ... the RNA Sequencing (RNA Seq) market for the years ... tools and reagents, data analysis, and services. ... the RNA-Sequencing market such as RNA-Sequencing tools and reagents, ... factors affecting each segment and forecast their market growth, ...
(Date:3/3/2016)... , March 3, 2016  FlexTech, a SEMI Strategic ... of Innovation, Research & Development, Leadership in Education, and, ... is the 9 th year of the FLEXI ... companies and individuals from past years . Judging ... a pre-described set of criteria, by a panel of ...
Breaking Biology News(10 mins):